Search Results for: 58

— Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 — — Conference Call Today, August 14, 2014, at 8:30 a.m. (EDT); U.S. Participants Call (877) 870-4263 or Join Webcast at http://www.videonewswire.com/event.asp?id=100224 — ROCKVILLE, Md., Aug. 14, […]

— Company Expects to Initiate C. difficile Clinical Trials in 2014 — ROCKVILLE, Md., June 30, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of

ROCKVILLE, Md., May 20, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 3rd Annual Marcum LLP MicroCap Conference on Thursday, May 29, 2014 in New York

— Conference Call Today, May 15, 2014, at 8:30 a.m. (EDT) — ROCKVILLE, Md., May 15, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three months ended March 31, 2014, and

— Conference Call Scheduled for Today, April 30, 2014 at 9 AM ET– ROCKVILLE, Md., April 30, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, will host a conference call today to discuss in further detail the

— UCLA Researcher Reports Adjunctive Trimesta was Associated with Reduced Relapse Rate of 47 Percent — ROCKVILLE, Md., April 29, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, reported today that the University of California, Los

ROCKVILLE, Md., March 10, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases,

ROCKVILLE, Md., Feb. 4, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 10, 2014, at 10:00 a.m.

— Conference Call Today, November 14, at 10 a.m. Eastern Time — ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three and nine months ended September 30, 2013 and provided an

— Progress Cited On Three Infectious Disease Programs, Including Two Programs in Collaboration with Intrexon Corporation; C. difficile Prophylactic is Lead Anti-Infective Candidate — ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for